Rocket One Inc. (RKTO) stock
Close on Nov 17, 2026Market cap $7.89MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $7.89M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.96
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$13.32M
- EPS, diluted
- -$0.83
- Book value per share
- $0.40
- Diluted shares
- 21M
Trading
- Previous close
- $0.32
- Open
- $0.32
- Day's range
- $0.30 – $0.32
- Volume
- 258,851
- Average volume (20 days)
- 284,219
- 52-week range
- $0.30 – $2.45
- RSI (14 days)
- 19.2
- Volatility (1 year)
- 148.9%
- Relative volume
- 0.54×
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | RKTO | S&P 500 | Difference | RKTO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.5% | -4.0% | −33.4 pts | ||
| 3 months | -58.6% | -5.0% | −53.6 pts | ||
| Year to date | -68.0% | +8.2% | −76.2 pts | ||
| 1 year | -72.9% | +11.2% | −84.1 pts | ||
| 3 years | -70.7% | +68.5% | −139.2 pts | -33.6% | +19.0% |
| 5 years | -98.6% | +67.3% | −165.9 pts | -57.7% | +10.8% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Rocket One filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Rocket One
Pharmaceutical Preparations
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new generation therapies designed to address unmet medical needs. The company's development pipeline features drug candidates targeting various conditions across oncology, dermatology, allergy, and neurology. Key pipeline assets include HT-001, a topical formulation for treating skin toxicities resulting from cancer therapies; HT-KIT, a targeted therapeutic for mast cell-derived neoplasms and anaphylaxis; and HT-ALZ, an asset aimed at treating and preventing Alzheimer’s disease and other neuroinflammatory conditions. Additional programs comprise BioLexa for atopic dermatitis, HT-004 for asthma and allergies, and HT-VA for obesity. The company creates these therapies primarily for patients requiring specialized interventions.
Company profile, executives and historyRocket One stock: common questions
What is Rocket One's stock price?
RKTO closed at $0.32 on Nov 17, 2026, down 1.25% on the day. Over the past 52 weeks it traded between $0.30 and $2.45.
What is Rocket One's market cap?
Rocket One was worth $7.89M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is RKTO's P/E ratio?
Rocket One lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.83), so it has no meaningful P/E ratio.
Does Rocket One pay a dividend?
No. Rocket One has not paid a cash dividend over the last twelve months.
How has RKTO stock performed over the past year?
Including dividends, RKTO returned -72.9% over the past year, against +11.2% for the S&P 500.
How many RKTO shares are sold short?
1M shares were sold short at the latest FINRA report, 2.78% of the float, or 2.3 days of average trading volume.
Who are Rocket One's competitors?
Companies most similar to Rocket One by business, industry and size include RCKT, GRCE, SNGX, SNDX, HIND.
See a number that looks wrong?